We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

SemBioSys Completes pre-IND Meeting with U.S. FDA for APO AIMilano

News   Aug 12, 2009

 
SemBioSys Completes pre-IND Meeting with U.S. FDA for APO AIMilano
 
 
Advertisement
 

RELATED ARTICLES

New Cancer Drug Targeting DNA Repair Shows Promise in Early-Stage Trial

News

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial – highlighting the potential of a new class of drugs known as ATR inhibitors.

READ MORE

Phase 3 Trial Assesses Dual-Antibody Injection's Ability To Prevent SARS-CoV-2 Infection

News

A Phase III, randomized, double-blinded, placebo-controlled trial will help to determine if the dual-antibody treatment, REGN-COV2, can prevent infection in individuals who share a home with someone who has been diagnosed with COVID-19.

READ MORE

Ultrapotent Compound Could Help Combat C. difficile

News

Scientists from Purdue University have advanced novel compounds that they have designed to help treat patients with Clostridioides difficile.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE